KMT2D mutation + TMB-H	Non Small Cell Lung Cancer	KMT2D mutation + TMB-H	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
KMT2D mutation + TMB-H	Non Small Cell Lung Cancer	KMT2D mutation + TMB-H	Non Small Cell Lung Cancer	PD1 inhibitor + CTLA4 inhibitor Sensitive: B - Late Trials PD1 inhibitor + CTLA4 inhibitor Sensitive : B	PD1 inhibitor + CTLA4 inhibitor Sensitive: B - Late Trials PD1 inhibitor + CTLA4 inhibitor Sensitive : B
KMT2D mutation + TMB-H	Colorectal Cancer	KMT2D mutation + TMB-H	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3

KMT2D mutation + TMB-H

Associations